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Hermansky-Pudlak syndrome (HPS) is a recessive disorder with bleeding diathesis, which has been
linked to platelet granule defects. Both platelet granules and endothelial Weibel-Palade bodies (WPBs)
are members of lysosome-related organelles (LROs) whose formation is regulated by HPS protein
associated complexes such as BLOC (biogenesis of lysosome-related organelles complex) -1, -2, -3, AP-3
(adaptor protein complex-3) and HOPS (homotypic fusion and protein sorting complex). Von Willebrand
factor (VWF) is critical to hemostasis, which is stored in a highly-multimerized form as tubules in the
WPBs. In this study, we found the defective, but varying, release of VWF into plasma after desmopressin
(DDAVP) stimulation in HPS1 (BLOC-3 subunit), HPS6 (BLOC-2 subunit), and HPS9 (BLOC-1 subunit)
deﬁcient mice. In particular, VWF tubulation, a critical step in VWF maturation, was impaired in HPS6
deﬁcient WPBs. This likely reﬂects a defective endothelium, contributing to the bleeding tendency in HPS
mice or patients. The differentially defective regulated release of VWF in these HPS mouse models
suggests the need for precise HPS genotyping before DDAVP administration to HPS patients.
Copyright © 2016, The Authors. Institute of Genetics and Developmental Biology, Chinese Academy of
Sciences, and Genetics Society of China. Published by Elsevier Limited and Science Press. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Weibel-Palade bodies (WPBs) are secretory organelles in
endothelial cells. They are large elongated rod shaped granules
surrounded by a limiting membrane, with an internal tubular
structure visible by electron microscopy (EM) (Weibel and Palade,
1964). Bioactive molecules that function in hemostasis, inﬂamma-
tion, angiogenesis and wound healing are stored in WPBs, and can
be released by exocytosis in response to endothelial activation
(Rondaij et al., 2006;Metcalf et al., 2008). The hemostatic factor von
Willebrand factor (VWF) is themajor content protein ofWPBs. VWF
has a highly complex biosynthesis, beginning with dimerization in
the ER (endoplasmic reticulum), and subsequent formation of VWF
tubules, allowing for multimerization and propeptide cleavage in a
process that begins in the trans-Golgi network (TGN) and continuesliwei@bch.com.cn (W. Li).
of Genetics and Developmental B
cess article under the CC BY licenduring subsequent maturation (Fowler et al., 1985; Vischer and
Wagner, 1994; Purvis and Sadler, 2004; Huang et al., 2008;
Springer, 2011). At secretagogue-triggered exocytosis, the VWF
multimer unfurls into the ﬂowing plasma as a long ﬁlament, highly
active in platelet recruitment. VWF tubulation andmultimerization
as well as the length of WPB are essential to the formation of long
platelet-catching strings (Michaux et al., 2006; Nightingale et al.,
2009; Ferraro et al., 2014).
WPBs undergo complex multi-stage processes during their
initial biogenesis and maturation stage (Metcalf et al., 2008;
Nightingale and Cutler, 2013). WPB initial formation at the TGN is
dependent on an AP-1 (adaptor protein complex-1)/clathrin coat
that is essential to VWF folding into tubules and thus generation of
elongated WPBs (Lui-Roberts et al., 2005). While some WPB com-
ponents, such as P-selectin and IL6, are recruited during initial
formation of immature electron-lucent WPBs with relatively few
disorganized VWF tubules at the TGN, others are delivered to
mature electron-dense WPBs with highly-ordered VWF tubules.
For example, the P-selectin co-factor CD63 is delivered to matureiology, Chinese Academy of Sciences, and Genetics Society of China. Published by
se (http://creativecommons.org/licenses/by/4.0/).
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on WPBs only late during their biogenesis when they tend to
accumulate near the cell periphery (Hannah et al., 2003; Romani de
Wit et al., 2003; Harrison-Lavoie et al., 2006; Zenner et al., 2007;
Valentijn et al., 2008, 2011; Berriman et al., 2009). Further, VWF
defects in forming tubules or in multimerization can cause mis-
shaped WPBs (Michaux et al., 2003, 2006), and interference with
cellular machinery including aftiphilin or Rab27a can also cause
defective multimerization of VWF (Nightingale and Cutler, 2013).
The close relationships between WPB shape and VWF folding and
multimerization are clear. However, the targeting of other WPB
components, the cytoplasmic machinery that supports WPB for-
mation, and the regulatory mechanisms controlling WPB biogen-
esis and exocytosis still require much further investigation.
The importance of such studies can be inferred from the fact that
VWF unable to form high molecular weight (MW)multimers is one
cause of von Willebrand disease (VWD), the most common
inherited bleeding disorder (Sadler et al., 2000), yet elevated levels
of highly-multimerized (HM) VWF in the blood can lead to vascular
occlusions, as in thrombotic thrombocytopenic purpura (TTP) (Levy
et al., 2001). Results from animal studies suggest that VWF deﬁ-
ciency is athero-protective, and in general, VWF multimerization is
closely related to atherosclerotic processes (Griggs et al., 1981;
Bilora et al., 1999; Methia et al., 2001; van Galen et al., 2012). The
amount and structure of plasma VWF are thus important factors in
vascular homeostasis.
WPB is a member of the family of lysosome-related organelles
(LROs) (Wei and Li, 2013). LRO biogenesis is precisely regulated by
HPS (Hermansky-Pudlak syndrome) protein associated complexes
(HPACs), such as the BLOC (biogenesis of lysosome-related
organelles complex) -1, -2, -3, AP-3 (adaptor protein complex-3)
and HOPS (homotypic fusion and protein sorting complex) com-
plexes. Mutations in most of the HPS genes in mice or in humans
lead to a bleeding tendency, hypopigmentation and other LRO de-
fects (Wei and Li, 2013). The bleeding diathesis has been linked to
platelet granule defects (Wei and Li, 2013; Meng et al., 2015).
However, except for AP-3, the functions of these HPACs in WPB
biogenesis are largely unclear. Thus despite the importance of
endothelial VWF to hemostasis and the differential effects of des-
mopressin (DDAVP) on HPS patients (Van Dorp et al., 1990; Zatik
et al., 2002; Cordova et al., 2005), how the structure and function
of VWF and WPB are affected in HPS patients has not been thor-
oughly established. In this study, we compared DDAVP-triggered
VWF secretion into plasma in different HPS mouse mutants with
the C56BL/6J background, pa (pallid, Hps9 /, BLOC-1 deﬁciency),
ru (ruby eye,Hps6 /, BLOC-2 deﬁciency), and ep (pale ear,Hps1 /,
BLOC-3 deﬁciency) and found a range of defects in the stimulated
release of VWF multimers that affect both response to DDAVP
treatment and hemostasis in HPS patients.
2. Results
2.1. Stimulated secretion of highly-multimerized (HM) VWF was
impaired in pa, ru, or ep deﬁcient mice
The secretion pattern of HM forms of VWF in the plasma
immediately after endothelial activation most closely reﬂects the
state of VWF within WPB and thus allows for an indirect assess-
ment of the extent of VWF multimerization within the endothelial
cells (ECs) in vivo (Nightingale et al., 2009). DDAVP, used to trigger
VWF exocytosis in patients (Mannucci, 1997) and inWT (wild-type)
mice (Rybaltowski et al., 2011), led to a signiﬁcant increase in both
total and HM VWF by 5 min post-injection, and this increase
remained for around 20 min before resolution (Fig. 1A, a and a0). In
pamice, the responsewas delayed by 15min post-injection (Fig. 1B,b and b0) when a signiﬁcant (albeit reduced) increase in HM (b0) but
not total (b) VWF was seen. In ru mice, there was no increase in
total (c) or HM (c0) VWF at any time points (Fig. 1C, c and c0). A small
increase in total (d) as well as HM (d0) VWF brieﬂy appeared at
5 min in ep mice (Fig. 1D, d and d0). Thus, both ru and ep mice
showed very little regulated release of HM VWF. Consistently, in
each strain of mouse the total plasma VWF levels in pa, ru and pe
mice changed over time after stimulation in a similar way to the
levels of HM VWF present (Fig. 1E). However, the basal VWF levels
in WT and mutant mouse plasma were almost the same when
compared by immunoblotting (Fig. 1F and G). Furthermore, the
secretion patterns of VWF multimers under non-stimulated status
(Fig. 1AeD, at each 00 lane) were almost normal in those three
mutant mice. This indicated that only the stimulated secretion of
VWF (mainly reﬂecting the VWF stored in WPBs) but not the basal
or constitutive secretion of VWF was affected in pa, ru, and ep
deﬁcient mice. These data suggest that different HPS proteins act
differentially in VWF release, implying differential functions in
WPB biogenesis and/or exocytosis.
2.2. WPBs were misshaped in ru mice
We concentrated further studies on the ru mice as showing the
most extreme defects in VWF. The altered secretion of HM VWF
from cells with defective organelle-forming cellular machinery
may result from impaired biogenesis, abnormal exocytosis, or both.
As there is HM VWF as well as some basal/constitutive secretion in
rumouse plasma (Fig.1C), this deﬁciency does not cause a complete
failure of formation as in an AP-1 deﬁciency (Lui-Roberts et al.,
2005). Since VWF biosynthesis and WPB morphology are so
tightly linked, we determined the morphological characteristics of
WPBs in primary ECs isolated from WT and mutant mice. Immu-
noﬂuorescent staining with VWF antibodies revealed the typical
elongated WPBs in WT ECs (Fig. 2A, a), but these were only rarely
seen in ru ECs (Fig. 2B, b). However, we observed WPB structures
similar to those of WT ECs in pa or ep ECs (Fig. 4). To gain an un-
biased comparison of the WPB structure in WT versus ru cells, we
carried out an automated quantitative morphometric analysis of
immunoﬂuorescent images (Ferraro et al., 2014). VWF positive or-
ganelles (green) whose Feret's diameter was greater than 0.3 mm
were counted as WPBs, and their distribution was plotted (in an
empirical cumulative distribution) as a function of Feret's diameter
(Fig. 2C). The distribution of WPBs in ru ECs shifted towards shorter
Feret's diameters compared with that in WT ECs. Using the differ-
ential plot for ruminusWT (Fig. 2D), we can see that in the positive
range there were more WPBs in ru ECs than in WT ECs, and in the
negative range there were less WPBs in ru ECs than in WT ECs. It
was conﬁrmed that there were moreWPBs distributed in the range
of shorter Feret's diameters in ru ECs than in WT ECs. This suggests
that the WPBs in the ECs from ru mice are mostly spherical rather
than elongated. Because the tubulation of VWF within WPBs is
essential to drive the elongated shape of WPB, such spherical WPBs
in ru ECs imply that the formation of VWF tubules from VWF
multimers may be abnormal in these cells.
2.3. WPBs containing organized tubular structure were decreased
in ru ECs
To conﬁrm that the misshaped WPBs in ru mice do have an
impaired tubular structure, we analyzed the ultrastructure ofWPBs
using transmission electron microscopy (TEM). We deﬁned two
types ofWPBs (Fig. 3A) in our TEM images from the aorta ofWTand
mutant mice. Type 1 WPBs have a highly ordered internal tubular
structure, whereas type 2 WPBs are internally disorganized. In
Fig. 3A, representative cross sections and longitudinal sections of
Fig. 1. Stimulated secretion of VWF multimers was abnormal in pa, ru or ep mice. AeD: Representative Western blots of VWF multimers from single examplar mice are shown.
DDAVP (50 mg/kg) was injected into the caudal vein of 12-week-old male mice. After 0, 5, 10, 15, 20 and 30 min, the mouse plasma specimens were collected and the VWF multimers
in the plasma of wild-type (WT) mice (A), pa (BLOC-1 HPS9 deﬁciency) mice (B), ru (BLOC-2 HPS6 deﬁciency) mice (C), and ep (BLOC-3 HPS1 deﬁciency) mice (D) were analyzed by
Western blotting after separation on SDS agarose gels. aed: The cumulative quantitation of total VWF corresponding to (AeD) at each time point normalized by that of 0 min are
shown. a0ed0: The cumulative quantization of the highly-multimerized (HM) VWF (all VWF upwards from 10 bands from the top) corresponding to (AeD) at each time point
normalized by that of 0 min are shown. Multimer gels were analyzed using NIH Image J software. Stars indicate the signiﬁcance: *P < 0.05, **P < 0.01; 3 mice were used in each
group. E: Representative Western blots of increased VWF showed that the total amount of changed plasma VWF after DDAVP stimulation had similar patterns to HM VWF (AeD). F:
Representative Western blots of unchanged total VWF in plasma under non-stimulated status of WT, pa, ru and ep mice are shown. G: The quantiﬁcation of total VWF (F) in plasma
from non-stimulated WT, pa, ru and ep mice (P > 0.05). Three mice were used in each group.
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the WPBs found among the TEM images taken from aorta were
cross sections. The longitudinal sections were rarer. The WPBs of
WT and mutant mice were categorized and the percentages of eachtype of WPB are shown in Fig. 3B. The type 1 WPBs were less
common in ru mice than in controls. In contrast, there were no
signiﬁcant differences in the amounts of these two types in the pa
and ep mice compared with the WT mice. These results are
Fig. 2. WPBs were misshaped in ru mice. A and B: Representative immunoﬂuorescence images of primary ECs are shown. ECs from WT (A) and ru (BLOC-2 HPS6 deﬁciency) (B)
were isolated from 4-week-old male mice and cultured for 10 days. After immunoﬂuorescence staining of VWF (green), WPBs were examined under a confocal microscope. Typical
elongated WPBs in WT ECs were rarer in ru ECs. Scale bar: 5 mm. a and b: The corresponding magniﬁed regions (white boxes) of A and B showed that WPBs were misshaped in ru
ECs. Scale bar: 2 mm. C: Quantiﬁcation analysis of the Feret's diameters of WPBs in WT and ru ECs. The VWF positive organelles (green in A and B) whose Feret's diameter is greater
than 0.3 mmwere counted as WPB. The images were analyzed with NIH Image J software. The distribution of WPBs was plotted as an empirical cumulative distribution as a function
of their Feret's diameters. The distribution of WPBs in ru ECs shifted towards shorter Feret's diameters compared with that in WT ECs. The total number of WPBs analyzed: 4900
WPBs fromWT ECs, 2551 WPBs from ru ECs, *** P < 0.001. D: A differential plot of the Feret's diameter of ruWPBs minus that of WT WPBs. There were more WPBs in ru ECs than in
WT ECs in the positive range, while in the negative range there were less WPBs in ru ECs than in WT ECs. More WPBs were distributed in the range of shorter Feret's diameter in ru
ECs than in WT ECs.
Fig. 3. The WPBs containing organized tubular structures were decreased in ru ECs. A: Representative electron micrographs of WPBs are shown. The aorta was separated from WT
and pa, ru and epmice (12-week-old male mice) and ﬁxed in 2% paraformaldehyde, 2.5% glutaraldehyde and 0.1% tannic acid in 0.1 mol/L phosphate buffer. The representative cross
sections and longitudinal sections of type 1 and type 2 WPBs are shown. Type 1 WPBs has highly-ordered tubular structure inside. Type 2 WPBs has unclear and disorganized
tubular structure inside. Scale bar: 200 nm. B: WPBs of WT and mutant mice were counted, respectively. The total number of WPBs analyzed: 754 WPBs from three WT mice, 754
WPBs from three pamice, 730 WPBs from three rumice, and 794 WPBs from three epmice. The percentages of each type of WPBs in total WPBs are shown. The average percentage
of type 1 WPB in ru mice (61.0 ± 2.8%) was decreased compared with that in WT mice (77.4 ± 1.0%), in pa mice (73.0 ± 2.7%) and in ep mice (76.0 ± 2.5%). * P < 0.05; N.S., no
signiﬁcance; three mice were used in each group.
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Fig. 4. Neutralization treatment altered the elongated shape of WPBs in WT, pa and ep ECs, but not in ru ECs. AeD: Representative immunoﬂuorescence images of the primary ECs
are shown. Isolated ECs fromWT, pa, ru and epmice (4-week-old male mice) were cultured for 10 days (AeD) and treated with 20 mmol/L NH4Cl in growth medium for 60 min (A′e
D′), and then underwent immunoﬂuorescence staining of VWF (green). Scale bar: 5 mm. aed: Corresponding magniﬁed regions (white boxes) of A to D. The WPBs fromWT, pa and
ep ECs became round after neutralization treatment (a0 , b0 and d0) compared with their elongated shapes before the treatment (a, b and d). While the WPBs in ru ECs were round-
shaped both before (c) and after (c0) the neutralization treatment. Scale bar: 5 mm. E: Quantiﬁcation of the mean Feret's diameters of WPBs in WT mice and mutant mice before and
after NH4Cl treatment is shown. The VWF positive organelles (green in AeD) whose Feret's diameter is above 0.3 mm were counted as WPB. The images were analyzed with NIH
Image J software. The total number of WPBs analyzed: ncontrol ¼ 1 669, nNH4Cl ¼ 1588 in WT ECs; ncontrol ¼ 1 799, nNH4Cl ¼ 1847 in pa ECs; ncontrol ¼ 1 643, nNH4Cl ¼ 1807 in ru ECs;
ncontrol ¼ 1783, nNH4Cl ¼ 1728 in ep ECs. *** P < 0.001; N.S., no signiﬁcance.
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impaired in ru mice.2.4. Neutralization treatment altered the elongated shape of WPBs
in WT, pa and ep ECs, but not in ru ECs
During VWF biosynthesis, dimerization in the ER is followed by
further folding in the increasingly acidic environment of the TGN to
facilitate the formation of a tubular spiral structure which gener-
ates the elongated shape of WPBs, and that also facilitates correct
multimerization (Vischer and Wagner, 1994; Huang et al., 2008).
The misshaped WPBs and the decrease of organized VWF tubular
structures in ru ECs seen by EM prompted us to explore this issue
further. Treating the ECs with neutralizing reagents such as mon-
ensin, NH4Cl, or chloroquine, which neutralizes the pH of acidic
organelles, results in most WPBs becoming spherical within 1 h
(Michaux et al., 2006). The extent of the effect of NH4Cl on WPB
shape will depend on how their tubular VWF is, i.e., genetically-
generated defective folding of VWF will reduce the change in
WPB length seen after incubation with NH4Cl.
To quantify the degree of folding of VWF, we treated the primary
ECs fromWTand mutant mice with NH4Cl. As shown in Fig. 4A and
A0 , consistent with a previous report (Michaux et al., 2006), the
majority of WPBs in WT ECs became round after the neutralization
treatment. Similar results were observed in pa (Fig. 4 B and B0) and
ep ECs (Fig. 4D and D0). However, the WPBs in ru ECs were already
rounded before the neutralization treatment (Fig. 4C and C0). These
misshapedWPBs (Fig. 2) were ru-speciﬁc (not seen in Fig. 4A, B and
D, and no change in morphometry in Fig. 4E). These results suggest
that HPS6 deﬁciency likely affects the tubulation of VWF inWPBs, a
critical step in VWF biosynthesis.2.5. VWF dispersion and the ability to unfurl into long ﬁlaments
were impaired in ru ECs
During exocytosis of WPBs, once facing the neutral pH of
plasma, the pro-peptides of VWF dissociate from the mature mul-
timers and the VWF unfurls into long ﬁlaments to recruit platelets
(Michaux et al., 2006). It has been shown that VWF tubulation is
essential for WPB elongation and VWF unfurling (Michaux et al.,
2006). To independently conﬁrm that VWF tubulation was
impaired in ru ECs, the detergent Triton X-100 was used to treat ECs
not under ﬂow in neutral pH (pH 7.2) to destroy the membranes
surrounding VWF tubules, leaving the VWF multimers to disperse
in situ when they can form blobs, tangles and even sometimes
unfurl into long ﬁlaments in vitro. As shown in Fig. 5, the dispersion
of VWF into clumps, tangles and short ﬁlaments appeared at 20min
of detergent treatment inWT, pa and ep ECs (Fig. 5A0 , B0 and D0), and
longer ﬁlaments were sometimes visible at 60min (Fig. 5A0 0 , B0 0 and
D00). However, very few smaller structures, let alone the longer
ﬁlaments, were visible in ru ECs during this time period (Fig. 5C0and
C0 0). This is consistent with the prediction that VWF distribution in
the absence of a limiting membrane and their ability to generate
long ﬁlaments would be altered in ru ECs due to the lack of the
tubular structures found in mature WPBs. This result again is
consistent with defective VWF tubulation in ru ECs.
3. Discussion
WPB, a member of the LRO family (Wei and Li, 2013), must
utilize similar cellular machinery to that of other LROs in their
biogenesis. However, while it has been shown that the AP-3 com-
plex is involved in the delivery of CD63 to WPB (Harrison-Lavoie
et al., 2006), any speciﬁc roles for other HPS protein associated
Fig. 5. VWF dispersion and the ability to generate large surface structures were
affected in ru ECs. AeD: Representative immunoﬂuorescence images of the primary
ECs are shown. ECs fromWT, pa, ru and epmice (4-week-old male mice) were cultured
for 10 days (AeD), then treated with 1% TritonX-100 in growth medium for 20 min
(A′eD′) or 60 min (A00eD00) on ice. After immunoﬂuorescence staining of VWF
(green), the in situ dispersion and formation of VWF “blobs” and tangles were
observed under a confocal microscope. The arrowheads represent potential classic
ﬁlaments, occasionally present even though these cells were not exposed to ﬂow.
The arrows represent longer ﬁlaments. No apparent longer ﬁlament was visible in ru
ECs even after treated for 60 min. Scale bar: 5 mm. aed: The corresponding magniﬁed
regions (white boxes) of AeD show the longer ﬁlaments in WT, pa and ep ECs but not
in ru ECs after treated for 60 min.
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major functions of WPB is to support the formation and storage of
HM VWF for the release into blood after secretagogue stimulation.
In HPS6 deﬁcient WPBs, VWF tubulation (a critical step in VWF
multimerization and in producing VWF that can form blobs, larger
tangles and even occasionally unfurl into long strings) (Michaux
et al., 2006)) was impaired. Our results demonstrate that HPS6 is
required for this aspect of WPB biogenesis, although further details
of the underlying molecular mechanism are as yet unknown. One
possible explanation might lie in the need for an acidic milieu to
support tubule formation. We therefore speculate that HPS6 may
affect the delivery of machinery required for acidiﬁcation of WPB,
explaining the failure of NH4Cl to signiﬁcantly alter the shape of the
WPB within ru ECs. Whether a HPS6 deﬁciency affects the intra-
TGN/WPB pH therefore warrants future investigation.
In this study, the secretion of VWF multimers after DDAVP in-
jection was abnormal with different patterns in HPS9, HPS6 or
HPS1 deﬁcient mice compared with that in WT mice. A failure to
secrete in response to DDAVP might reﬂect a reduced pool of
untangled andmultimerized VWF. VWF in an unfolded state within
the WPBs could either fail to multimerize correctly, leaving only
low MW materials, or could be multimerized but unable to form
tubules, and thus in either case would not be unfurled and
stretched out for ADAMTS13 cleavage to proceed, precluding it
from joining the usual plasma multimer population. The shapes of
WPBs in HPS1 and HPS9 deﬁcient mice are not changed, suggesting
that HPS1 or HPS9 likely does not affect the tubulation of WPBs.
However, the secretion of VWF after DDAVP stimulation wasdelayed in HPS9 deﬁcient mice and was very short in HPS1 deﬁ-
cient mice (Fig. 1). The delay of the secretion of high MW VWF
multimers in HPS9 deﬁcient mice suggests that the exocytosis of
WPB or the unfurling process might be affected. In HPS1 deﬁcient
mice, the DDAVP-responsive secretion of HM VWF was very brief.
In addition to the kind of problems raised above, further defects
could include a smaller readily-releasable pool of mature WPBs, or
indeed the accelerated removal of impaired VWF from the circu-
lation. Our data, showing unimpaired levels of fully multimerized
VWF in non-stimulated mice (Fig. 1) suggest that at least some
multimerization is occurring, even within the ru endothelium, and
that the loss of a regulated response to DDAVP, the main change
seen here, does not affect this. Surprisingly, the loss of elongated
WPB shape in ru ECs is not associated with a parallel loss of mul-
timerization in plasma, implying that tubulation is not always
required formultimerization, or that the population ofWPB serving
the regulated secretory pathway is selectively defective.
These unexpected and complex phenotypes lead us to conclude
not only that there is still a great deal to understand about the
packaging and secretion of VWF, but also that the detailed roles of
HPS9, HPS6 and HPS1 in VWF biosynthesis, WPB biogenesis or
exocytosis, which all require further studies. Our results also sug-
gest not only that these HPS proteins do contribute to the bleeding
diathesis of HPS, but also that different HPS proteins act differen-
tially, consistent with the variable patient responses to DDAVP as
described below. We therefore propose that the likely altered
response to endogenous secretagogue stimulation will differen-
tially contribute to the bleeding tendency in the HPS mice or
patients.
It must be emphasized that the steady-state plasma VWF levels
of the HPS mutants did not change, but that the changes occurred
after DDAVP treatment when multimerized VWF is released for
stopping bleeding. While DDAVP has been suggested for the
symptomatic treatment of bleeding diathesis in HPS patients
(Huizing et al., 2008), variable responses to DDAVP administration
in HPS patients (Van Dorp et al., 1990; Zatik et al., 2002; Cordova
et al., 2005) have been documented. In particular, 89% of Puerto
Rican HPS patients, who are mostly HPS-1 or HPS-3 (forming the
same BLOC-2 complex with HPS5 and HPS6 proteins), were re-
ported as poor responses to DDAVP treatment (Cordova et al.,
2005). Our results in mice suggest that the administration of
DDAVP to the HPS-6 (BLOC-2) or HPS-1 (BLOC-3) subtype patients
maywell be differentially reduced in efﬁcacy. In the era of precision
medicine, these ﬁndings suggest that genotyping of HPS patients
might be explicative of the results of DDAVP administration.
Interestingly, the ru mutant showed a protective role in
atherosclerosis after an atherogenic diet, while the ep mice had
lesions and reduced life span similar to control C57BL/6J mice. In
addition, the atherosclerotic lesions did not correlate with the
platelet serotonin levels (Paigen et al., 1990). It has been shown that
VWF deﬁciency or loss of function has a protective effect on
atherosclerosis (van Galen et al., 2012). These studies suggest that
other factors such as VWF may be responsible for the variability of
susceptibility to atherosclerosis in these mouse HPS mutants. The
defects in the secretion of HM VWF upon DDAVP treatment in the
rumice could confer the resistance for atherosclerosis in thesemice
or HPS6 patients.
4. Materials and methods
4.1. Mice
pa, ru, ep mutant mice (pa e HPS9 deﬁciency in BLOC-1 (Huang
et al., 1999), ru e HPS6 deﬁciency in BLOC-2 (Zhang et al., 2003), ep
e HPS1 deﬁciency in BLOC-3 (Gardner et al., 1997)) and the control
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Laboratory (Maine, USA) that were maintained in Dr. Richard T.
Swank's laboratory. All these mutants arose from spontaneous
mutations in C57BL/6J background. These mice were bred in the
animal facility of the Institute of Genetics and Developmental
Biology (IGDB), Chinese Academy of Sciences. The mutant mice
were maintained as homozygotes through intercrosses of hetero-
zygotes. The genotypes of these mutants were conﬁrmed by PCR
genotyping methods based on the nature of the mutations (Li et al.,
2006). Male mice of each genotype were used to avoid potentially
confounding hormonal effects of the estrous cycle in females. All
animal procedures were approved by the Institutional Animal Care
and Use Committee of IGDB.
4.2. Isolation of primary endothelial cells (ECs)
Primary ECs were isolated as previously described (Jin et al.,
2012). Dynabeads coated with Sheep anti-Rat IgG (Invitrogen,
catalog# 110.35, USA) were pre-treated by incubating the beads
with Rat anti-mouse PECAM-1 (CD31) antibody (BD Biosciences,
catalog# 553370, USA) at 4C overnight, washing four times with
PBS þ 0.1% BSA and then resuspending beads in PBS þ 0.1% BSA.
Two weeks old male mice were euthanized by injection of so-
dium pentobarbital and dipped in 70% ethanol for 5 min. The
heart was removed and minced, then incubated in 0.2% colla-
genase type II (Invitrogen, catalog# 17101-015) with Hank's
buffered salt solution (HBSS: dissolve 200 mg of KCl, 30 mg of
KH2PO4, 175 mg of NaHCO3, 4 g of NaCl, 24 mg of Na2HPO4,
500 mg D-glucose, and 3 g HEPES in 500 mL distilled water;
adjust pH to 7.4) at 37C with gentle rotation for 45 min. The
suspension was ﬁltered through a 70-mm disposable cell strainer
(Corning, catalog# 352350, USA) and spun at 400  g for 8 min at
4C. The cells were resuspended in DMEM and incubated with
20 mL/mL pre-treated anti-mouse PECAM-1 coated Dynabeads for
30 min at 4C. Beads were then washed 3e5 times until super-
natant is clear, then incubated with 0.05% trypsin-EDTA at 37C
for 5 min before removal of the beads. Cells were then spun
down at 400  g for 10 min, and the cell pellet was resuspended
in growth medium and plated in a 6-well plate.
4.3. Cell culture and treatments
Mouse primary ECs were grown in EBM-2 medium (Lonza,
catalog# CC-4176, USA) at 37C in 5% CO2. NH4Cl (Sigma-Aldrich,
catalog# A9434, USA) was used in 20 mmol/L ﬁnal concentration in
growthmedium. Triton X-100 (Sigma-Aldrich, catalog# T8787) was
used at 1% in PBS after pH adjustment. The Triton X-100 treated
cells were applied on ice for 20 min or 60 min. All the procedures
were followed as described (Michaux et al., 2006).
4.4. Antibodies and immunoﬂuorescence imaging
Polyclonal rabbit anti-human VWF antibody was purchased
from DAKO (Carpinteria, catalog# A0082, USA). Immunoﬂuores-
cence staining and confocal microscopy were carried out as pre-
viously described (Zhang et al., 2014). Cells were grown on glass
cover slips in 24-well plates and ﬁxed with freshly prepared 4%
paraformaldehyde for 30 min, washed three times with 0.01 mol/L
phosphate buffer (PBS, pH 7.4), permeabilized with 0.3% Triton X-
100 in PBS for 15 min, and blocked in 0.01 mol/L PBS containing 1%
BSA for 1 h. Fixed cells were incubated with anti-VWF antibodies
(1:2000 in PBS containing 1% BSA) overnight at 4C, then washed
three times with 0.01 mol/L PBS containing 0.1% Triton X-100
before incubating with Alexa Fluor 488-conjugated secondary
antibody (Life technologies, catalog# A21206, USA) for 1 h at roomtemperature. Then the glass cover slips were mounted with
Mounting Medium with DAPI (ZSGB, catalog# ZLI-9557, China).
Images were acquired with a 100 objective of ECLIPSE Ti-C2
confocal microscope (Nikon, Japan). The images were analyzed
with NIH Image J software. Morphometric analysis of images was
previously described (Ferraro et al., 2014).
4.5. VWF multimer analysis
DDAVP (Sigma-Aldrich, catalog# V1005) powder was dissolved
in 0.9% NaCl solution. DDAVP (20 ng/mL) was injected into the
caudal vein of 12-week-old male mice at a dose of 50 mg/kg. After 0,
5, 10, 15, 20 and 30 min, the tail blood of mouse at each time point
were collected and centrifuged at 4000  g for 10 min. The su-
pernatant plasma was collected for immunoblotting.
VWF multimer analysis was previously described (Nightingale
et al., 2009). 1.2% agarose gels were prepared by dissolving Sea-
kem high gelling temperature agarose (Lonza, catalog# 50041) in
0.375 mol/L Tris (pH 8.8) with SDS added to a ﬁnal concentration of
0.1%. Mouse plasma samples (3 mL) were loaded in 50 mmol/L Tris
pH 8.0, 1% SDS, 5% glycerol and 0.002% bromophenol blue. Gels
were run at 30 V for 16 h (Beijing Liu Yi, China) before transfer to a
nitrocellulose membrane, labeled with rabbit anti-VWF antibody
followed by a HRP conjugated anti-rabbit secondary antibody
(ZSGB, catalog# ZB-2301, China) and developed by chem-
iluminescence (SuperSignal West Pico, Thermo, catalog# NCI5080,
USA). The multimers of each lane on the same gel were arranged
according to the MW. We chose the top 10 bands as a cutoff for
quantiﬁcation of high MW since there is no universally accepted
multimer level above which they are high MW as against low MW,
we therefore used a pragmatic solution and chose the highest
multimer at which we can be sure of matching the bands between
samples. Multimer gels were analyzed using NIH Image J software.
4.6. Electron microscopy
Mice were euthanized by injection of sodium pentobarbital and
dipped in 70% ethanol for 5 min. The thoracic cavity was incised,
the sternum cut, and the aorta cleaned by perfusing with ﬁxing
buffer (2% paraformaldehyde and 2.5% glutaraldehyde) from the
left ventricle. The aorta was separated gently and the surrounding
connective tissue and fat were removed, the vessel was cut into
1 mm tubes, and ﬁxed in 2% paraformaldehyde, 2.5% glutaralde-
hyde and 0.1% tannic acid in 0.1 mol/L phosphate buffer at 4C
overnight. After washing, the tubes were post-ﬁxed in 1% osmium
tetroxide for 1 h, dehydrated in an ascending series of dilution of
acetone and impregnated in Spurr. Blocks were polymerized at
70C for 12 h, sections (60 nm) cut with a Leica microtome
(Ultracut, Germany), stained with lead citrate, and viewed with a
JEM 1400 electron microscope (JEOL, Japan).
4.7. Statistical analysis
The data are shown as the mean ± S.E.M. Comparisons were
statistically tested using the Student's t-test. Difference of P < 0.05
was considered as statistically signiﬁcant. For blinded quantiﬁca-
tion, an automated unbiased high-throughput computer-driven
morphometric methodology was used and unknown genotypes
were not informative to the observers.
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